

“An 1886 theatre poster advertising a production of the pantomime Aladdin” (Wikipedia), PD-US

ALADIN: A New Approach for Drug–Target Interaction Prediction

Krisztian Buza^a, Ladislav Peška^b

^a Knowledge Discovery and Machine Learning
Rheinische Friedrich-Wilhelms-Universität Bonn, Germany

^b Faculty of Mathematics and Physics
Charles University, Prague, Czech Republic

buza@cs.uni-bonn.de

peska@ksi.mff.cuni.cz

Supplementary material: <http://www.biointelligence.hu/dti>



RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT



Outline


- Motivation
- Bipatite Local Models
- Our approach: Advanced Local Drug-Target Interaction Prediction (ALADIN)
- Experiments
- Outlook and Conclusion

Motivation

- Better understanding of the pharmacology of drugs
- Prediction of adverse effects
- Drug repurposing
 - use of an existing medicine to treat a disease that has not been treated with that drug yet
 - For example, *sildenafil* was designed to treat heart diseases, but it was not effective. However it turned out to be useful in case of erectile disorders → became known as *viagra*.
- drug discovery is expensive and needs long time
(up to \$1.8 billion, more than 10 years on average)

Morgan, S. et al.: The cost of drug development: a systematic review. Health Policy 100.1 (2011): 4-17.

Bipartite Local Models (BLM)




Bleakley, K., Yamanishi, Y.: Supervised prediction of drug–target interactions using bipartite local models. *Bioinformatics* 25(18), 2397–2403 (2009)

Our approach: Advanced Local Drug–Target Interaction Prediction (ALADIN)


- Local model in BLM: EC k NN – a hubness-aware regressor
 - In case of “new” drugs/targets, BLM is inappropriate → use weighted profile
- Enhanced representation of drugs and targets in a multi-modal similarity space
- Projection-based ensemble

Local model: ECkNN – nearest neighbor regression with hubness-aware error correction (illustration with $k = 1$)



Buza, K., Nanopoulos, A., Nagy, G.: Nearest neighbor regression in the presence of bad hubs. Knowledge-Based Systems 86, 250–260 (2015)

Local model: ECkNN – nearest neighbor regression with hubness-aware error correction (illustration with $k = 1$)



Buza, K., Nanopoulos, A., Nagy, G.: Nearest neighbor regression in the presence of bad hubs. Knowledge-Based Systems 86, 250–260 (2015)

Enhanced similarity-based representation of drugs and targets

drug–target interaction matrix

Drug 1	1		1		
Drug 2			1		1
Drug 3				1	1
Drug 4		1		1	
	Target 1	Target 2	Target 3	Target 4	Target 5

Enhanced similarity-based representation of drugs

Drug 1	1	0.6	0.1	0.2	1	0.33	0	0
Drug 2	0.6	1	0.3	0.1	0.33	1	0.33	0
Drug 3	0.1	0.3	1	0.7	0	0.33	1	0.33
Drug 4	0.2	0.1	0.7	1	0	0	0.33	1

chemical similarities
to all the drugs

Jaccard-similarities to all drugs
(based on the interaction matrix)


Enhanced similarity-based representation of targets

Target 1	1	0.1	0.2	0.3	0.1	1	0	0.5	0	0
Target 2	0.1	1	0.2	0.5	0.1	0	1	0	0.5	0
Target 3	0.2	0.2	1	0.1	0.4	0.5	0	1	0	0.3
Target 4	0.3	0.5	0.1	1	0.6	0	0.5	0	1	0.3
Target 5	0.1	0.1	0.4	0.6	1	0	0	0.3	0.3	1

genomic similarities
to all the targets

Jaccard-similarities to all targets
(based on the interaction matrix)

Projection-based ensemble



Algorithm 1 Advanced Local Drug–Target Interaction Prediction (ALADIN)

Require: Drug–Target interaction matrix I , Drug–drug similarity matrix S^D , Target–target similarity matrix S^T , number of nearest neighbors k , ensemble size N , number of selected features F_D, F_T


Ensure: Likelihood of drug–target interactions

- 1: $D \leftarrow$ enhanced similarity-based representations of drugs
 - 2: $T \leftarrow$ enhanced similarity-based representations of targets
 - 3: **for** $l = 1 \dots N$ **do**
 - 4: $D' \leftarrow$ random subset of D with F_D features
 - 5: $T' \leftarrow$ random subset of T with F_T features
 - 6: Predict interaction scores with BLM using $ECkNN$ as local model and D' and T' as the representation of drugs and targets.
 (Use the weighted profile approach instead of BLM in case of new drugs/targets.)
 - 7: **end for**
 - 8: Average the predictions made in each execution of the loop
-

Experimental Settings

- Data: publicly available real-world drug-target interaction datasets: Enzyme, Ion Channel, G-protein coupled receptors (GPCR), Nuclear Receptors (NR), and Kinase
- Experimental protocol: 5x5 fold cross-validation
- Evaluation metrics:
 - Area under the ROC curve (AUC)
 - Area under Precision-Recall Curve (AUPR)
 - Statistical significance tests (t-test) at significance level of $p=0.01$
- Baselines:
 - BLM-NII: bipartite local models with „neighbor-based interaction-profile inferring“
 - NepLapRLS: „net Laplacian regularized least squares“
 - WNN-GIP: combination of weighted nearest neighbor and Gaussian interaction profile kernels
- Hyperparameters of ALADIN and the baselines were learned with grid search on the training data

Experimental Results




Outlook: Recommender Systems for Drug–Target Interaction Prediction




Computer Methods and Programs in Biomedicine

Volume 152, December 2017, Pages 15–21

Drug-target interaction prediction: A Bayesian ranking approach

Ladislav Peska^{a, b, *}, , , Krisztian Buza^{b, c}, Júlia Koller^d

 [Show more](#)

<https://doi.org/10.1016/j.cmpb.2017.09.003> [Get rights and content](#)

Highlights

- Proposing BRDTI method for per-drug ranking of DTIs.
- Performed comparative evaluation of BRDTI w.r.t. AUC and per-drug nDCG.
- BRDTI achieved best average results on predicting new targets for existing drugs.

Conclusions

- Drug-target interaction prediction is one of the most prominent applications of machine learning in the pharmaceutical industry
- In our work, we extended bipartite local models (BLM) and showed that the resulting approach outperforms BLM and other drug-target interaction prediction techniques
- Prediction of drug-target interactions is related to those machine learning tasks that have been considered in the recommender systems community